InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Last trade$0.6702
Day change+$0.0702 (+11.70%)
Day range$0.57 – $0.68
Volume314,700
Market cap$28M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$28.07M
Price / earnings
—
Price / book
0.89×
Price / sales
2.59×
EV / sales
1.19×
EV / EBITDA
-0.24×
Profitability
Earnings per share
-$1.12
Return on assets
-117.56%
Return on equity
-166.55%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.8×
Quick ratio
3.52×
Cash ratio
1.57×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$42.46M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NSPR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$1.77M
$3.4M
$3.15M
$2.52M
$1.78M
$1.53M
$1.95M
$1.81M
Cost of revenue
$2.55M
$2.71M
$1.97M
$1.66M
$1.47M
$1.24M
$1.48M
$1.4M
Gross profit
-$774K
$687K
$1.18M
$864K
$313K
$292K
$469K
$414K
Selling, general and administrative
$9.38M
$9.9M
$9.79M
$10.28M
$9.5M
$7.69M
$6.14M
$4.96M
Research and development
$4.3M
$4.76M
$3.48M
$3.64M
$3.83M
$4.06M
$3.69M
$3.92M
Total operating expenses
$13.67M
$14.67M
$13.26M
$13.92M
$13.33M
$11.75M
$9.84M
$8.88M
Operating income
-$14.45M
-$13.98M
-$12.08M
-$13.05M
-$13.02M
-$11.46M
-$9.37M
-$8.46M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$14.32M
-$13.69M
-$11.7M
-$12.71M
-$13.15M
-$11.17M
-$9.12M
-$7.89M
Income taxes
$0
$0
$63K
$0
$0
$0
$59K
$0
Net income
-$14.32M
-$13.69M
-$11.76M
-$12.71M
-$13.15M
-$11.17M
-$9.17M
-$7.89M
Net income attributable to common shareholders
-$14.32M
-$13.69M
-$11.76M
-$12.71M
-$13.15M
-$11.17M
-$9.17M
-$7.89M
EBITDA
-$14.29M
-$13.83M
-$11.94M
-$12.92M
-$12.91M
-$11.36M
-$9.29M
-$8.39M
Basic earnings per share
-$0.17
-$0.16
-$0.14
-$0.17
-$0.26
-$0.22
-$0.19
-$0.16
Diluted earnings per share
-$0.17
-$0.16
-$0.14
-$0.17
-$0.26
-$0.22
-$0.19
-$0.16
Recent news
Company coverage with links to the original publishers.
InspireMD (NSPR) beat earnings expectations with a loss of $0.11 per share versus consensus estimate of $0.15, representing a 26.67% earnings surprise. The company also surpassed revenue estimates at $2.24 million. However, shares have declined 55.1% year-to-date, significantly underperforming the S&P 500's 11.3% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
908 Devices Inc. (MASS) beat earnings expectations with a loss of $0.11 per share versus consensus estimate of $0.16 loss, representing a 31.25% earnings surprise. Revenue of $18.95 million also surpassed estimates by 2.09%. The stock has gained 119.2% year-to-date, significantly outperforming the S&P 500's 10.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
LivaNova (LIVN) reported Q3 2026 earnings of $1.23 per share, beating consensus estimates of $1.03 and delivering a 19.42% surprise. Revenue reached $393.1 million, surpassing estimates by 3.43%. The company has outperformed market expectations for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries.
InspireMD amended Series J and K warrants affecting approximately 14.3 million shares, aligning the exercise trigger with anticipated FDA approval of CGuard Prime 80 cm expected in Q4 2026. The amendments could provide up to $11 million in gross proceeds to fund the commercial launch of the TCAR product, which targets an addressable market of over 35,000 annual procedures in the U.S.
InspireMD announced the first patient enrollment in the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system used with CGuard Prime 80 cm stent in TCAR procedures. The prospective, multi-center study will enroll approximately 103 subjects to evaluate safety and efficacy for treating carotid artery stenosis. The company projects 70,000 TCAR procedures annually in the U.S. by 2030.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.